Sage Therapeutics Inc (NASDAQ: SAGE) stock enjoyed a major increase of 16.9% on 1/8/24. The shares closed at $25.10. Moreover, trading volume in this advance was unusually high at 163% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 13.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, SAGE is expected to continue to be Value Creation neutral.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Sage Therapeutics has a slightly negative Appreciation Score of 36 and a very low Power Rating of 2, triggering the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment